

REMARKS/ARGUMENTS

In this specification, the paragraph beginning at page 14, line 12, has been amended to include the sequence identifier of the newly added sequence listing. Page 5 has been amended to correct a typographical error in the structure shown in the paragraph beginning at line 5; handwritten amendments to the structure are shown in the Appendix.

Claims 1-33 remain in this application. Claims 11, 14, 17, and 21 are currently amended to add Crohn's disease in the selection of inflammatory response, and to correct a typographical error. Support for the amendment adding Crohn's disease can be found at page 21, lines 27-29 and in Examples 2 and 12. Claim 31 has been amended to correct a typographical error in the structure; handwritten amendments to the structure are shown in the Appendix. No new matter is added.

Amendments to the title

Applicant has amended the title above to replace the title as filed with the phrase "Immunomodulatory Polymeric Antigens for Treating Inflammatory Pathologies". Although the original filed title on page 1 of the specification recites the identical title, PTO records contain a misspelling of the word "Pathologies." This amendment is submitted to correct the title of record.

Amendments to the specification

Applicant has amended the specification at page 14 to include the sequence identifier SEQ ID NO: 1 in the description.

Page 5 has been amended to correct a typographical error in the structure shown in the paragraph beginning at line 5. Handwritten amendments to the structure are shown in the Appendix. Applicant submits that a person of skill in the art would readily identify the error, and would understand that the inclusion of the additional oxygen atom was unintentional. Applicant submits that no new matter is added by this amendment.

Claim amendments

Applicant has amended claims 11, 14, 17, and 21 to include Crohn's disease in the list of inflammatory responses. Support for this amendment can be found at page 21, lines 27-29, where it is stated that Crohn's disease is a model of inflammation in which IL10 has been shown to be efficacious; and in Examples 2 and 12, where it is shown that administration of Compound 15 leads to the expression of IL10.

Claim 31 has been amended to correct a typographical error in the structure. Handwritten amendments to the structure are shown in the Appendix. Applicant submits that a person of skill in the art would readily identify the error, and would understand that the inclusion of the additional oxygen atom was unintentional. Applicant submits that no new matter is added by this amendment.

It is respectfully submitted that the above-identified application is now in condition for favourable reconsideration and prompt allowance of these claims is respectfully requested. Should the Examiner believe that anything further is desirable in order to place the application in better condition for allowance, the Examiner is invited to contact the applicant's undersigned attorney at the telephone number listed below.

Respectfully submitted

/David W. Maher, Ph.D./

David W. Maher

Reg. No. 40,077

BioTechnology Law Group

(858) 228-7829

Fax: (858) 350-9691